Yogen Saunthararajah

24PUBLICATIONS
84CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular medicineEpidemiological modellingGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 25, 2026
Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias.

|Jul 10, 2026
H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics.

|Oct 08, 2025
Combining drugs that bypass p53 to treat TP53-mutated leukemias.

Sudipta Biswas, Zeinab Albadry M Zahran, Xiaorong Gu

|Jul 17, 2025
Epigenetic drug remedies for SCD root cause pathophysiology.

Yogen Saunthararajah, Donald Lavelle

|Sep 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri

|Jul 07, 2023
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

Henry Lau, Philip G Woost, Ute Friedrich

Pageof 4

Frequent Collaborators

3 joint publications

Mendel Goldfinger

3 joint publications

Babal K Jha

2 joint publications

Misam Zawit

2 joint publications

Simona Pagliuca